“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH. Overall, 39% of those who received a ...

Data from a Mayo Clinic study show, despite some reports of discomfort and dissatisfaction, a majority of patients receiving penile prosthesis are satisfied 1 year in.

Prostate cancer incidence and mortality are increasing, with over 313,000 diagnoses and 35,000 deaths projected for 2025. Screening practices, influenced by the US Preventive Services Task Force, have ...

"If a practice has determined in writing that there are insurers whose policies advised that they will not accept this code, it seems reasonable not to report that code to that insurer even when ...

"It really remains to be seen whether we can expand this to care for other types of urological inpatients," says Timothy D. Lyon, MD. In this video, Timothy D. Lyon, MD, discusses the Urology Practice ...

Wilms tumor growth patterns differ based on the specific predisposition gene variant and its developmental timing. Around 30% of children with Wilms tumor have a mutation in a predisposition gene, ...

"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says ...

"There are actually no data to support that 1 neuromodulation is better than another based on disease severity, and this is based on the systematic review done for the OAB guideline," says Anne ...

MiR-371a-3p demonstrates high sensitivity and specificity, outperforming traditional tumor markers in testicular cancer diagnosis and monitoring. MiR-371a-3p shows potential in early relapse detection ...

Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options ...

Urologists emphasized the importance of AUA guidelines, patient context, and clinical judgment in managing low-grade UTUC. Challenges in diagnosis and treatment include obtaining adequate biopsies and ...

Panelists discuss how low-risk non–muscle-invasive bladder cancer (NMIBC) requires transurethral resection of bladder tumor (TURBT) with surveillance. Intermediate-risk disease needs adjuvant ...